Kornimate/medical-research-clean huggingface dataset:
active hexose correlated compound in tuberculosis-hiv (human immunodeficiency virus) infection

Conditions: Tuberculosis; Human Immunodeficiency Virus

Summary: background active hexose correlated compound is assumed to have a positive effect on immunity, including induce a phagocytic response, reduce tumor resistance, and cytokine response including interferon-gamma and interleukins. tuberculosis patients with concurrent human immunodeficiency virus (hiv) might have benefit when receiving active hexose compound during tuberculosis treatment purposes 1. to assess the clinical changes of patients who receive active hexose compound as an adjuvant to tuberculosis therapy in patients with hiv 2. to assess the difference of pro-inflammatory cytokines between standard therapy and active hexose compound adjuvant methods a clinical trial involving patients with tuberculosis-hiv infection hypothesis 1. clinical improvement is significantly different where the group who receive active compound will have the better clinical outcome 2. lower proinflammatory cytokines are observed in people who receive active compound

population : lung tuberculosis patient with hiv infection design : double-blind randomized control trial at the outpatient setting randomization simple randomization proposed number of participants : using the difference between two independent means of duration to sputum conversion 1. type 1 error 5% 2. power of study 80% 3. effect size 0.5 4. dropout rate 20% total participant 122 proposed analysis 1. time-to-event analysis using cox regression for the duration of sputum conversion and radiology resolution 2. linear mixed model for continuous dependent variable

Eligibility criteria:
inclusion criteria: 1. newly-diagnosed lung tuberculosis case who will receive a 6-month regiment 2. not pregnant 3. diagnosed with hiv exclusion criteria: 1. patient with liver dysfunction 2. patient with drug-resistant 3. severe malnutrition 4. refuse to be involved

Keywords: active hexose correlated compound tuberculosis-hiv cytokine sputum conversion
a study of cfi-400945 with or without azacitidine in patients with aml, mds or cmml

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; AML; MDS; CMML

Summary: the purpose of this study is to test the safety of an investigational drug called cfi-400945 alone and in combination with azacitidine.

this study will be evaluating the safety and tolerability of cfi-400945 in subjects with acute myeloid leukemia, myelodysplastic syndrome or chronic myelomonocytic leukemia. the study is designed to build on encouraging data from another study and to obtain further safety, efficacy, pharmacokinetics (pk) and pharmacodynamics (pd) data of cfi-400945.

Eligibility criteria:
inclusion criteria: 1. patients must be \>18 years of age 2. for parts 1a and 1b, the following malignancy types will be included: 1. relapsed or refractory aml. 2. mds, after prior hypomethylating agents. 3. cmml, with progressive disease/lack of response after hypomethylating agents for parts 1a and 1b, patients may have relapsed or refractory disease. 3. for parts 2a and 2b, the following malignancy types will be included: 1. relapsed or refractory aml. 2. mds patients should be limited to high risk disease 3. mds or cmml should be previously untreated and patients with aml may have relapsed or refractory disease; 4. have clinically acceptable laboratory screening results (i.e., clinical chemistry, hematology, and urinalysis) within certain limits per protocol. 5. have an eastern cooperative oncology group (ecog) performance status of 0 or 1. exclusion criteria: 1. patients who have received investigational therapy, radiotherapy, immunotherapy, monoclonal antibodies, or chemotherapy within 14 days or 5 half-lives (whichever is shorter) 2. allogeneic or autologous transplant for aml with infusion of stem cells within 90 days before cycle 1 day 1, or on active immunosuppressive therapy for graft-versus-host disease (gvhd) or gvhd prophylaxis within 2 weeks of cycle 1 day 1. 3. any grade ≥ 2 persistent non-hematological toxicity related to allogeneic transplant, such as those requiring systemic immunosuppressive therapy.

Keywords: polo-like kinase 4 plk4 serine/threonine kinase polo-like kinase 4 cfi-400945 945 polo-like kinase 4 inhibitors/antagonists hematologic malignancies plk-4 uhn university health network treadwell treadwell therapeutics treadwell tx
cryoablation versus bcg instillation therapy for high-risk nmibc

Conditions: Bladder Cancer

Summary: this trial plans to enroll 190 eligible patients and randomize them into two groups with a 1:1 ratio, with 95 patients in each group. the experimental group will receive immediate cryoablation therapy at the resection site after tur, while the control group will only undergo tur and receive conventional bcg instillation therapy postoperatively. both groups of subjects will undergo re-turbt or cystoscopy 10-12 weeks after surgery to compare the tumor-free residual rates and adverse events between the two groups.


Eligibility criteria:
inclusion criteria: 1. aged between 18 and 85, male or female; 2. preoperatively diagnosed with t1 stage or meeting the criteria for high-risk bladder cancer (accord with the "2023 nccn bladder cancer guidelines"); 3. good compliance and able to cooperate with observation; 4. able to understand the purpose of the trial, agree to participate in this study, and have signed the informed consent form. exclusion criteria: 1. patients with severe infectious diseases such as bacteremia and toxemia; 2. patients with severe coagulation dysfunction; 3. patients with severe heart, brain, lung, liver, kidney and other diseases who cannot tolerate surgery; 4. patients with other concurrent malignancies; 5. postoperative pathological diagnosis of bladder cancer patients in tis, ta, or t2 stages; 6. preoperative ct/mri assessment showing tumor invasion beyond the bladder (t3 stage or above); 7. preoperative assessment indicating distant metastasis or enlarged pelvic lymph nodes; 8. pregnant or breastfeeding women; 9. other situations assessed by researchers as unsuitable for inclusion in this study, such as inappropriate anatomical structure, mental or psychological disorders.
36-month clinical performance of different restorative materials in the treatment of root caries lesions

Conditions: Root Caries

Summary: this is a split-mouth, randomized clinical study that evaluating the 36-month performance of different restorative materials in the treatment of root caries lesions. a total of 110 restorations were randomly placed, half using resin composite (spectrum tph3) and the other half using the resin-modified glass ionomer cement (riva light cure). restorations were evaluated at the baseline, 6, 12, 18,24 and 36 months according to the usphs criteria.

the aim of the study was to comparatively assess the 36-month clinical performance of a micro hybrid resin composite and resin-modified glass ionomer cement in root caries lesions. thirty-three patients with at least two root caries lesions participated in this study. a total of 110 restorations were randomly placed, half using resin composite (spectrum tph3) and the other half using the resin-modified glass ionomer cement (riva light cure). restorations were evaluated at the baseline, 6, 12, 18, 24 and 36 months. the data were analyzed with pearson's chi-square, cochran's q, friedman tests and logistic regression analysis (p=0.05).

Eligibility criteria:
inclusion criteria: * root caries lesions (at least 1mm depth) exclusion criteria: * complex medical history * poor dental hygiene/infrequent practise of oral hygiene habits * severe or chronic periodontitis * extreme carious activity * heavy bruxism * very deep (closer than 0.5 mm to the pulp) or superficial lesions (shallower than 1mm) * previously restored and abutment teeth for bridge or removable dental prostheses

Keywords: micro hybrid resin composite resin-modified glass ionomer split-mouth randomized clinical trial
clinically indicated magnetic resonance imaging in patients with cardiac devices

Conditions: Arrhythmias, Cardiac

Summary: patients with implanted cardiac devices who meet appropriate entrance criteria undergo clinically indicated magnetic resonance (mr) imaging studies using an established safety protocol.

this prospective cohort study to use an established mri device safety protocol to decrease the risk of clinically indicated mr imaging in patients with implantable cardiac devices. all devices will undergo a complete interrogation and testing of thresholds, sensing, battery voltage and impedances prior to and following imaging. pre-mri, devices will be programmed to setting that will ensure mri safety. during imaging, patients will blood pressure, heart rate and o2 sat level will be monitored continuously.

Eligibility criteria:
inclusion criteria: * patients with an emergent or absolute need for mr imaging and ppm or certain icd's exclusion criteria: * pacemaker dependent patients with icd's * patients with other contraindication to mri

Keywords: mri, pacemakers, defibrillator
study of wve-003 in patients with huntington's disease

Conditions: Huntington Disease

Summary: this is a phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pk, and pd of wve-003 in adult patients with early-manifest hd who carry the targeted single nucleotide polymorphism (snp) - snp3.


Eligibility criteria:
inclusion criteria: 1. presence of the a variant of snp3 on the same allele as the pathogenic cag triplet expansion 2. ambulatory, male or female patients aged ≥25 to ≤60 years 3. clinical diagnostic motor features of hd, defined as unified huntington's disease rating scale (uhdrs) diagnostic confidence score = 4 4. uhdrs total functional capacity scores ≥9 and ≤13 exclusion criteria: 1. malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years 2. received any other study drug, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer, with the exception of the following: a. received wve-120101 or wve-120102 within the last 3 months 3. implantable cns device that may interfere with ability to administer study drug via lumbar puncture or undergo mri scan 4. inability to undergo brain mri (with or without sedation) 5. bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture 6. previously received tominersen
mobile lung nodule observatory for worldwide, evidenced-based research

Conditions: Solitary Pulmonary Nodule

Summary: patients with lung nodules may develop a variety of potentially severe symptoms. these symptoms may impact a patient's quality of life and lead to difficult treatment. through this research program, the investigators want to understand the pathogenesis of the changes of these symptoms.

lung nodules can manifest as single or multiple independent lung consolidation shadow in form of quasi-circular. these lung nodules are surrounded by normal lung tissues, and will not cause pulmonary atelectasis. in some early standards, all the quasi-circular shadows within 6cm found in lung are categorized as lung nodules. however, according to current standards, the lesion within 3cm can be identified as lung nodules. with widespread use of lung cancer ct screening, lung nodules were identified more and more frequently. what is the optimal way to manage this ct finding? should we adopt surgical removal or just observation? an optimal solution is to determine a clearly defined standard of care that is easy to learn. we propose a method called "three plus two". the 'three' is a three-step testing method, and the 'two' means two alternative solutions. three-step testing method includes collecting medical history, non-invasive examination, and invasive examination. the two alternative solutions are surgical removal and follow-up observation. we have independently developed an application based on a smartphone platform. this platform will provide a novel evidence-based research method for observing the dynamic evolution of the lung nodules in patients. there have been no prior studies about managing this ct scan finding, either in china or internationally.

Eligibility criteria:
inclusion criteria: * age between 18 and 90 * there is a chest lesion less than 3cm width (examined by thin-section ct) * the patient or his family member owns a smartphone * signed informed consent * completed the installation and registration of mobile terminal software online * willing to complete a 10-year period of follow-up exclusion criteria: * not equipped with a smartphone * cannot complete the installation or registration of smartphone application software online * received prior chemotherapy medications for lung cancer or received lung surgical removal treatment

Keywords: researchkit ct screening early diagnosis lung cancer
diabetic autonomic neuropathy and left ventricular function

Conditions: Diabetes Mellitus

Summary: purpose: to investigate the effect of quinapril (q) or losartan (l) or their combination on definite diabetic autonomic neuropathy (dan) and left ventricular systolic and diastolic function (lvf) over a period of 4 years. patients-methods: fifty-nine patients with definite dan \[2 or more of the 4 cardiovascular reflex tests (crts) were abnormal\] were studied for 4 years. patients were randomly allocated in 3 groups receiving a, 20 mg q, b, 100 mg l and c, 20 mg q +100 mg l respectively. crts analyzed with mean circular resultant (mcr), valsalva index, 30:15 ratio and postural hypotension. lv function was investigated with radionuclide ventriculography (rnv) at rest. ejection fraction was used to assess lv systolic function, while peak filling rate, first third filling fraction, and atrial contribution to ventricular filling were used to investigate lv diastolic function. crts and rnv were performed at baseline and after 4 years.


Eligibility criteria:
inclusion criteria: 1. \>18 years old 2. diabetes mellitus 3. diabetic autonomic neuropathy exclusion criteria: 1. coronary artery disease 2. arterial hypertension 3. heart failure with reduced ejection fraction lvef\<40% 4. any contraindication to undergo radionuclide ventriculography
comparison of exercise intervention effects following lumbar microdiscectomy

Conditions: Injury of Nerve Root of Lumbar and Sacral Spine

Summary: low back pain is common, costly and affecting up to 80% of the population with the lumbar discectomy being a frequent spinal procedure for disc herniations. pain \& mobility impairments persist in patients following microdiscectomy with long term issues of back pain. the question remains as to why some patients recover quickly and without lasting difficulties while other patients persist with prolonged disability following the same surgery. the purpose of this study is to determine how to guide the patient towards full function and evaluate the timing to initiate strengthening, neurodynamics and a walking exercise program.

the direction of treatment for low back pain both surgically and conservatively seeks to improve function in both daily and sporting activities for all patients. the patients continuing to suffer from a significant level of pain, disability and reduced function following single level microdiscectomy may benefit from a multi-factorial approach. a reduction in neurodynamic mobility related to dural adhesions is considered to be a contributing factor in this persistent peripheral neuropathic pain. the clinical efficacy of this study will address an exercise protocol post surgery in order to provide an optimal approach in the prevention of scar tissue that may be contributing to persistent pain post microdiscectomy. mobility and motor control impairments are considered the consequence to the onset of pain. education, neurodynamics and stabilization exercises are instrumental in the recovery post microdiscectomy with a reduction in pain and disability and the goal towards full functioning. the introduction of a neurodynamic protocol as an early exercise intervention may serve to reduce pain inhibition resulting with improved mobility and motor control. the recording of step count per day following a lumbar microdiscectomy will serve to document daily and physical activity levels following surgery. the purpose of this study is to determine whether or not there is a significant difference in pain levels and lumbar mobility between an early exercise intervention group versus a late exercise intervention group post microdiscectomy.

Eligibility criteria:
inclusion criteria: * uncomplicated unilateral post-op microdiscectomy l3-4, l4-5, l5-s1 * radicular symptoms within one year of surgical intervention * ability to understand english or french for instructional purposes * able to participate in physical activity exclusion criteria: * under the age of 18 years or over the age of 65 years * diagnosis of inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis * neoplasm * metabolic bone disease * cauda equine syndrome * neurological disorders ie multiple sclerosis, parkinsons * compression of the spinal cord * uncontrolled cardiovascular or respiratory disease * peripheral vascular disease with sensory loss in the foot * discitis * pregnancy * previous spinal surgeries

Keywords: exercise lumbar microdiscectomy
brain health & wellness classes for veterans with traumatic brain injury

Conditions: Brain Injury Traumatic Mild; Post-traumatic Stress Disorder

Summary: this study is testing the usefulness of two types of brain health \& wellness classes for veterans with a history of concussion to improve mental health.

this is a pragmatic, randomized controlled trial of mindfulness-based stress reduction (mbsr) in 120 veterans with comorbid ptsd and chronic mtbi. half of the participants are randomly assigned to mbsr and the other half, to a brain health education class, which serves as an active control group. a battery of standardized psychological and cognitive measures are administered prior to and following the class interventions to assess change in response to the intervention, with an additional 6-month follow-up assessment to test for lasting changes. the primary outcome measures include the mayo-portland adaptability inventory iv (functional outcome), ptsd checklist (psychological outcome), and cognitive control test (cognitive outcome).

Eligibility criteria:
inclusion criteria: * 18-75 years old * chronic history (\>6 months) of one or more mtbis * current diagnosis of ptsd * at least one self-reported cognitive symptom exclusion criteria: * no history of other neurologic disease (e.g., tumor, stroke, dementia, parkinson's) * no history of major brain surgery * no history of moderate or severe tbi * no active alcohol or drug dependence or abuse within previous 30 days * no history of severe psychotic disorder (e.g., schizophrenia) * no current suicidal ideation/risk * no clinically severe medical illness requiring treatment

Keywords: mindfulness mindfulness-based stress reduction tbi anxiety ptsd veteran
insulin analogues and severe hypoglycaemia

Conditions: Type 1 Diabetes

Summary: severe hypoglycaemia is hampering the lives of many diabetic patients. the effect on the occurrence of severe hypoglycaemia during two different insulin regimens are to be investigated. in total, 250 hypoglycaemia prone type 1 diabetic patients will be randomised to receive analogue and human insulin for one year in random order. outcomes will be number of episodes of severe hypoglycaemia

the primary objective is to evaluate the effects of insulin analogue and human insulin on incidence of severe hypoglycaemia in type 1 diabetic patients prone to hypoglycaemia.secondary endpoints are effect on incidence of symptomatic and asymptomatic documented hypoglycaemia. study design: an open, randomised, controlled, cross-over multi-centre study. each treatment period lasts for one year. patients will be randomised to treatment with basal bolus therapy with insulin detemir / aspart and insulatard / actrapid in random order. endpoints will be assessed during the last 9 months of each treatment arm. patient population: 250 type 1 diabetic patients with a history of two or more episodes of severe hypoglycaemia during the preceding year. interventions: basal bolus therapy with insulin detemir / aspart and insulatard / human actrapid in random order. each treatment period lasts 12 months. methods: patients will record all events of severe hypoglycaemia, documented symptomatic and asymptomatic hypoglycaemia in a diary and report all events of severe hypoglycaemia by telephone within 24 hours. all patients will be instructed to do and record home blood glucose monitoring (smbg) i.e. 7 point profiles twice per week and nocturnal measurements once every month. outcomes: severe hypoglycaemia, documented symptomatic and asymptomatic hypoglycaemia efficacy: number of reported episodes of severe, documented symptomatic and asymptomatic hypoglycaemia during the last 9 months of treatment - during daytime and night time. safety: adverse reactions

Eligibility criteria:
inclusion criteria: * type 1 diabetes for 5 years. * age\>18 years. * two or more episodes of hypoglycaemia during the last year, exclusion criteria: * history of addisons disease * growth hormone deficiency or untreated myxoedema * cvd within 6 months * cancer within 5 years * alcohol or drug abuse * pregnant or lactating women * fertile women without effective contraception * participation in another trial within 30 days * inability to understand the informed consent

Keywords: diabetes insulin insulin analogues hypoglycaemia severe hypoglycaemia